Findings

What do systematic reviews say?

10 questions · 10 findings · 10 reviews · Epilepsy

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 10%Low 2 · 20%Moderate 5 · 50%High 2 · 20%

Lamotrigine vs placebo

Dizziness · people with drug‐resistant focal epilepsy

Summary of findings: lamotrigine probably leads to higher dizziness compared with placebo (moderate certainty).

1 finding from 1 review

Lamotrigine add‐on therapy for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
RR 1.76
13 studies · 1768 participants
Moderate

Any dose of lacosamide vs placebo

Dizziness · adults and children with drug‐resistant focal epilepsy

Any dose of lacosamide leads to higher dizziness compared with placebo (high certainty).

1 finding from 1 review

Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
RR 2.96
5 studies · 2199 participants
High

Sulthiame vs phenytoin

Dizziness · participants with epilepsy (GTCS)

Sulthiame showed no clear difference in dizziness compared with phenytoin (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 3.16 [0.18, 55.62]
1 study · 146 participants
Low

Tiagabine vs placebo control

Dizziness · people with drug‐resistant focal epilepsy

Tiagabine probably leads to higher dizziness compared with placebo control (moderate certainty).

1 finding from 1 review

Tiagabine add‐on therapy for drug‐resistant focal epilepsy 2019 · Cochrane Headline outcomes only
RR 1.69 [1.13, 2.51]
3 studies · 769 participants
Moderate

Carisbamate vs placebo

Dizziness · people with drug‐resistant focal epilepsy

It is very uncertain whether carisbamate changes adverse events: dizziness compared with placebo (very low certainty).

1 finding from 1 review

Carisbamate add‐on therapy for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 2.06 [1.23, 3.44]
4 studies · 2211 participants
Very low

Losigamone vs placebo

Dizziness · people with focal epilepsy

Losigamone probably leads to higher adverse event (dizziness) compared with placebo (moderate certainty).

1 finding from 1 review

Losigamone add‐on therapy for focal epilepsy 2019 · Cochrane Headline outcomes only
RR 3.82 [1.69, 8.64]
2 studies · 467 participants
Moderate

Rufinamide vs placebo

Frequency of adverse effects ‐ dizziness ( · people with drug‐resistant focal epilepsy

Rufinamide probably leads to higher adverse effects: dizziness compared with placebo (moderate certainty).

1 finding from 1 review

Rufinamide add‐on therapy for drug‐resistant epilepsy 2020 · Cochrane Headline outcomes only
RR 2.52 [1.9, 3.34]
3 studies · 1295 participants
Moderate

Flunarizine vs placebo

Frequency of adverse effects ‐ dizziness ( · patients with drug‐resistant epilepsy

Flunarizine showed no clear difference in adverse effects ‐ Dizziness No of patients with dizziness compared with placebo (high certainty).

1 finding from 1 review

Calcium antagonists as an add‐on therapy for drug‐resistant epilepsy 2013 · Cochrane Headline outcomes only
RR 1.82 [0.72, 4.61]
1 study · 93 participants
High

Zonisamide vs placebo

Frequency of adverse effects ‐ dizziness ( · people with focal epilepsy

Zonisamide probably leads to higher adverse effects: dizziness (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

Zonisamide add‐on therapy for focal epilepsy 2020 · Cochrane Headline outcomes only
RR 1.4
7 studies · 1429 participants
Moderate

Vigabatrin vs placebo

Adverse effects: dizziness, lightheadedness · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher adverse effects: dizziness/light‐headedness Duration of treatment… compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin add‐on therapy for drug‐resistant focal epilepsy 2020 · Cochrane Headline outcomes only
RR 1.74 [1.05, 2.87]
9 studies · 709 participants
Low